title: Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.
abstract: The recent development of chemotherapeutic proteasome inhibitors, such as bortezomib, has improved the outcomes of patients suffering from the plasma cell malignancy multiple myeloma. Unfortunately, many patients treated with these drugs still suffer relapsing disease due to treatment-induced upregulation of the antiapoptotic protein Mcl1. We have recently demonstrated that an oncolytic poxvirus, known as myxoma, can rapidly eliminate primary myeloma cells by inducing cellular apoptosis. The efficacy of myxoma treatment on proteasome inhibitor-relapsed or -refractory myeloma, however, remains unknown. We now demonstrate that myxoma-based elimination of myeloma is not affected by cellular resistance to proteasome inhibitors. Additionally, myxoma virus infection specifically prevents expression of Mcl1 following induction of the unfolded protein response, by blocking translation of the unfolded protein response activating transcription factor (ATF)4. These results suggest that myxoma-based oncolytic therapy represents an attractive option for myeloma patients whose disease is refractory to chemotherapeutic proteasome inhibitors due to upregulation of Mcl1.
authors: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
authors: Katherine M
authors: KM
authors: Dunlap
authors: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
authors: Mee Y
authors: MY
authors: Bartee
authors: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
authors: Eric
authors: E
authors: Bartee
keywords: drug resistance; oncolytic